{"id":56796,"date":"2026-02-10T23:22:06","date_gmt":"2026-02-10T15:22:06","guid":{"rendered":"https:\/\/flcube.com\/?p=56796"},"modified":"2026-02-10T23:22:07","modified_gmt":"2026-02-10T15:22:07","slug":"chia-tai-fenghai-licenses-fhnd5032-mir-124-inducer-to-formation-bio-for-500-million","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56796","title":{"rendered":"Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million"},"content":{"rendered":"\n<p><strong>Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH)<\/strong> has entered a <strong>strategic licensing agreement<\/strong> with <strong>Formation Bio<\/strong>, granting the <strong>US-based firm exclusive global rights<\/strong> (excluding Greater China) to <strong>FHND5032<\/strong>, an <strong>oral small-molecule miR-124 inducer<\/strong> for <strong>autoimmune diseases<\/strong>. The deal, valued at <strong>over USD 500 million<\/strong>, represents a <strong>first-in-class microRNA-targeting transaction<\/strong> with potential to transform chronic inflammatory disease management through <strong>durable epigenetic modulation<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-structure\">Transaction Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Jiangsu Chia Tai Fenghai Pharmaceutical (CTFH)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Formation Bio (US-based)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>FHND5032 \u2013 Oral small-molecule miR-124 inducer<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Global excluding Greater China (China, Hong Kong, Macau, Taiwan)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Upregulation of microRNA-124 (anti-inflammatory microRNA)<\/td><\/tr><tr><td><strong>Deal Value<\/strong><\/td><td><strong>&gt;USD 500 million<\/strong> total potential consideration<\/td><\/tr><tr><td><strong>Structure<\/strong><\/td><td>Equity stake in Kenmare Bio + upfront + milestones (R&amp;D, registration, commercialization) + royalties<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-amp-mechanism-of-action\">Technology Platform &amp; Mechanism of Action<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>FHND5032 Approach<\/th><th>Strategic Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Target<\/strong><\/td><td><strong>miR-124<\/strong> \u2013 Master regulatory microRNA with anti-inflammatory properties<\/td><td>First-in-class microRNA-targeting small molecule in autoimmune diseases<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td><strong>Oral small-molecule upregulation<\/strong> of endogenous miR-124 levels<\/td><td>Epigenetic modulation vs. protein-targeting biologics<\/td><\/tr><tr><td><strong>Pathophysiology<\/strong><\/td><td>miR-124 typically <strong>downregulated in inflammatory diseases<\/strong>; restoration addresses root cause<\/td><td>Potential for <strong>disease modification<\/strong> vs. symptomatic control<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td><strong>Oral, small-molecule<\/strong><\/td><td>Convenience advantage over injectable biologics; scalable manufacturing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biological Rationale:<\/strong> miR-124 regulates <strong>key immune drivers<\/strong> including microglial activation, macrophage polarization, and T-cell differentiation; elevation promotes <strong>M2 anti-inflammatory phenotype<\/strong> and suppresses <strong>pro-inflammatory cytokine production<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-indications-amp-market-opportunity\">Target Indications &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapeutic Area<\/th><th>Potential Application<\/th><th>Market Context<\/th><\/tr><\/thead><tbody><tr><td><strong>Rheumatoid Arthritis<\/strong><\/td><td>Chronic joint inflammation with miR-124 downregulation<\/td><td>$30B+ market dominated by TNF\/IL-6\/JAK inhibitors with durability limitations<\/td><\/tr><tr><td><strong>Inflammatory Bowel Disease<\/strong><\/td><td>Crohn&#8217;s disease and ulcerative colitis<\/td><td>Unmet need for oral, disease-modifying therapies beyond anti-integrins<\/td><\/tr><tr><td><strong>Multiple Sclerosis<\/strong><\/td><td>Neuroinflammation and demyelination<\/td><td>miR-124 critical for microglial homeostasis in CNS<\/td><\/tr><tr><td><strong>Systemic Lupus Erythematosus<\/strong><\/td><td>Multi-organ autoimmune dysfunction<\/td><td>High unmet need for steroid-sparing, durable remission agents<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-competitive-context\">Strategic Positioning &amp; Competitive Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Transaction Value<\/th><\/tr><\/thead><tbody><tr><td><strong>First microRNA licensing deal<\/strong> in autoimmune space<\/td><td>Validates CTFH&#8217;s <strong>epigenetic drug discovery platform<\/strong> and positions Formation Bio as pioneer in miRNA therapeutics<\/td><\/tr><tr><td><strong>Oral small-molecule format<\/strong><\/td><td>Addresses <strong>biologic fatigue<\/strong> and <strong>injection burden<\/strong> in chronic autoimmune management<\/td><\/tr><tr><td><strong>Disease modification potential<\/strong><\/td><td>miR-124 upregulation offers <strong>root-cause intervention<\/strong> vs. cytokine blockade symptom management<\/td><\/tr><tr><td><strong>Greater China retention<\/strong><\/td><td>CTFH retains <strong>domestic rights<\/strong> for world&#8217;s largest autoimmune market; Formation Bio handles high-bar US\/EU development<\/td><\/tr><tr><td><strong>Formation Bio AI integration<\/strong><\/td><td>Partnership leverages Formation&#8217;s <strong>tech-enabled drug development<\/strong> to accelerate clinical translation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-roadmap\">Development Roadmap<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Activity<\/th><th>Responsible Party<\/th><\/tr><\/thead><tbody><tr><td><strong>Current<\/strong><\/td><td>Preclinical optimization and IND-enabling studies<\/td><td>CTFH (China) \/ Formation Bio (ex-China)<\/td><\/tr><tr><td><strong>Near-term<\/strong><\/td><td>IND submissions to FDA and EMA<\/td><td>Formation Bio<\/td><\/tr><tr><td><strong>Clinical<\/strong><\/td><td>Phase I\/II autoimmune indication selection<\/td><td>Formation Bio (global), CTFH (China)<\/td><\/tr><tr><td><strong>Expansion<\/strong><\/td><td>Proof-of-concept in rheumatology, gastroenterology, or neurology<\/td><td>Data-driven indication prioritization<\/td><\/tr><tr><td><strong>Commercial<\/strong><\/td><td>US\/EU launch preparation and partnership optimization<\/td><td>Formation Bio<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding FHND5032 clinical development timelines, microRNA therapeutic validation in autoimmune diseases, and Formation Bio&#8217;s commercialization strategy. Actual results may differ due to miR-124 target validation risks, oral bioavailability challenges for microRNA modulators, and competitive responses from established autoimmune biologics manufacturers.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) has entered a strategic licensing agreement with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,2336,4176],"class_list":["post-56796","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-auto-immune","tag-chia-tai-fenghai-pharmaceutical","tag-formation-bio"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) has entered a strategic licensing agreement with Formation Bio, granting the US-based firm exclusive global rights (excluding Greater China) to FHND5032, an oral small-molecule miR-124 inducer for autoimmune diseases. The deal, valued at over USD 500 million, represents a first-in-class microRNA-targeting transaction with potential to transform chronic inflammatory disease management through durable epigenetic modulation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56796\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) has entered a strategic licensing agreement with Formation Bio, granting the US-based firm exclusive global rights (excluding Greater China) to FHND5032, an oral small-molecule miR-124 inducer for autoimmune diseases. The deal, valued at over USD 500 million, represents a first-in-class microRNA-targeting transaction with potential to transform chronic inflammatory disease management through durable epigenetic modulation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56796\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-10T15:22:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-10T15:22:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56796#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56796\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million\",\"datePublished\":\"2026-02-10T15:22:06+00:00\",\"dateModified\":\"2026-02-10T15:22:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56796\"},\"wordCount\":501,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Chia Tai Fenghai Pharmaceutical\",\"Formation Bio\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56796#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56796\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56796\",\"name\":\"Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-10T15:22:06+00:00\",\"dateModified\":\"2026-02-10T15:22:07+00:00\",\"description\":\"Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) has entered a strategic licensing agreement with Formation Bio, granting the US-based firm exclusive global rights (excluding Greater China) to FHND5032, an oral small-molecule miR-124 inducer for autoimmune diseases. The deal, valued at over USD 500 million, represents a first-in-class microRNA-targeting transaction with potential to transform chronic inflammatory disease management through durable epigenetic modulation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56796#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56796\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56796#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) has entered a strategic licensing agreement with Formation Bio, granting the US-based firm exclusive global rights (excluding Greater China) to FHND5032, an oral small-molecule miR-124 inducer for autoimmune diseases. The deal, valued at over USD 500 million, represents a first-in-class microRNA-targeting transaction with potential to transform chronic inflammatory disease management through durable epigenetic modulation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56796","og_locale":"en_US","og_type":"article","og_title":"Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million","og_description":"Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) has entered a strategic licensing agreement with Formation Bio, granting the US-based firm exclusive global rights (excluding Greater China) to FHND5032, an oral small-molecule miR-124 inducer for autoimmune diseases. The deal, valued at over USD 500 million, represents a first-in-class microRNA-targeting transaction with potential to transform chronic inflammatory disease management through durable epigenetic modulation.","og_url":"https:\/\/flcube.com\/?p=56796","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-10T15:22:06+00:00","article_modified_time":"2026-02-10T15:22:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56796#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56796"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million","datePublished":"2026-02-10T15:22:06+00:00","dateModified":"2026-02-10T15:22:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56796"},"wordCount":501,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Chia Tai Fenghai Pharmaceutical","Formation Bio"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56796#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56796","url":"https:\/\/flcube.com\/?p=56796","name":"Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-10T15:22:06+00:00","dateModified":"2026-02-10T15:22:07+00:00","description":"Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) has entered a strategic licensing agreement with Formation Bio, granting the US-based firm exclusive global rights (excluding Greater China) to FHND5032, an oral small-molecule miR-124 inducer for autoimmune diseases. The deal, valued at over USD 500 million, represents a first-in-class microRNA-targeting transaction with potential to transform chronic inflammatory disease management through durable epigenetic modulation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56796#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56796"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56796#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56796"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56796\/revisions"}],"predecessor-version":[{"id":56797,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56796\/revisions\/56797"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56796"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}